Lusutrombopag for thrombocytopenia in Chinese patients with chronic liver disease undergoing invasive procedures
ConclusionsLusutrombopag was effective in raising PLT, diminishing platelet transfusion requirement, and documented a safety profile like the placebo in CLD and severe thrombocytopenia patients in a Chinese cohort undergoing elective invasive procedures. Chinese clinical trial registration number: CTR20192384.
Source: Hepatology International - Category: Infectious Diseases Source Type: research
More News: Bleeding | China Health | Clinical Trials | Infectious Diseases | Liver | Liver Disease | Study | Thrombocytopenia | Urology & Nephrology